CD4/MHC Class II, CD8/MHC Class I). Pathogenic Steps Inhibited by Efalizumab: (a) T-cell activation by antigen in the lymph nodes, (b) T-cell binding to the endothelium with migration into the ...

Both the naive T- and B-cell receptor repertoire are generated by interaction with self-ligands, such as the major histocompatibility complex (MHC), which in turn can signal to T- and B-cells to ...